SKT Short Cognitive Performance Test and Activities of Daily Living in Dementia
Abstract
Using data from two randomized, placebo-controlled trials involving 806 outpatients, we performed linear regression analyses to evaluate how cognitive abilities in patients with dementia assessed by the SKT (Syndrom-Kurztest – Short Cognitive Performance Test) correlate with activities of daily living rated by means of the Activities of Daily Living International Scale (ADL-IS). There were significant correlations between SKT total score and ADL-IS total mean score at baseline (r = 0.52, p < .001) as well as between change in SKT total score and change in ADL-IS total mean score during the 24-week treatment period (r = 0.48, p < .001). Significant correlations with ADL-IS total mean scores were also found for both memory and attention/concentration subscores of the SKT.
References
2004). Validation of the Korean version of the Syndrom Kurztest (SKT): A short test for the assessment of memory and attention. Human Psychopharmacology Clinical and Experimental, 19, 495–501.
(1997). The Neuropsychiatric Inventory: Assessing psychopathology in dementia patients. Neurology, 48(Suppl. 6), S10–S16.
(1997). Note for guidance on medicinal products in the treatment of Alzheimer’s disease (CPMP/EWP/553/95 Corr.). London: European Medicines Evaluation Agency.
(2008). Guideline on medicinal products for the treatment of Alzheimer’s disease and other dementias (CPMP/EWP/553/95 Rev. 1). London: European Medicineds Agency.
. (1986). Manual zum SKT Formen A-E. Ein Kurztest zur Erfassung von Aufmerksamkeits- und Gedächtnisstörungen [
(SKT manual forms A-E. A short performance test to assess impairment of attention and memory ]. Ebersberg: Vless-Verlag.2004). The Short Cognitive Test (SKT) – A transcultural test for early detection and discrimination of dementia: A preliminary study in Brazil. Neurobiology of Aging, 25(Suppl. 2), 113.
(2001). Spanish validation of the Syndrom Kurztest (SKT). Alzheimer Disease and Associated Disorders, 15, 211–215.
(2012). Cognitive and neuropsychiatric symptom differences in early stages of Alzheimer’s disease: Kuopio ALSOVA Study. Dementia and Geriatric Cognitive Disorders Extra, 2, 209–218.
(1992). Moving from the question of efficacy to the question of therapeutic relevance: an exploratory reanalysis of a controlled clinical study of 130 inpatients with dementia syndrome taking piracetam. International Psychogeriatrics, 4, 25–43.
(2012). Ginkgo biloba extract EGb 761® in dementia with neuropsychiatric features: A randomized, placebo-controlled trial to confirm the efficacy and safety of a daily dose of 240 mg. Journal of Psychiatric Research, 46, 716–723.
(2011). Efficacy and safety of a once-daily formulation of Ginkgo biloba extract EGb 761 in dementia with neuropsychiatric features: A randomized controlled trial. International Journal of Geriatric Psychiatry, 26, 1186–1194.
(1993). Factor structure and scoring of the SKT test battery. Journal of Clinical Psychology, 49, 61–71.
(1997). Evidence of the cross-cultural stability of the factor structure of the SKT short test for assessing deficits of memory and attention. International Psychogeriatrics, 9, 139–153.
(2005). The TE4D-Cog: A new test for detecting early dementia in English-speaking populations. International Journal of Geriatric Psychiatry, 20, 1172–1179.
(1984). Clinical diagnosis of Alzheimer’s disease: Report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s Disease. Neurology, 34, 939–944.
(1999). Determination of normative criteria and validation of the SKT for use in Spanish-speaking populations. International Psychogeriatrics, 11, 171–180.
(2001). The Alzheimer’s Disease Activities of Daily Living International Scale (ADL-IS). International Psychogeriatrics, 13, 163–181.
(2011). The relationship of neuropsychological function to instrumental activities of daily living in mild cognitive impairment. International Journal of Geriatric Psychiatry, 26, 843–852.
(2010). The ADAS-cog and clinically meaningful change in the VISTA clinical trial of galantamine for Alzheimer’s disease. International Journal of Geriatric Psychiatry, 25, 191–201.
(1993). Vascular dementia: Diagnostic criteria for research studies. Report of the NINDS-AIREN International Workshop. Neurology, 43, 250–260.
(2007). The cognitive correlates of functional status: a review from the Committee on Research of the American Neuropsychiatric Association. The Journal of Neuropsychiatry and Clinical Neurosciences, 19, 249–265.
(2005). Prevalence and clinical correlates of neuropsychiatric symptoms in dementia. American Journal of Alzheimer’s Disease and Other Dementias, 20, 367–373.
(2013). Entwicklungsdiagnostik im Alter: Wie kann man unauffällige Leistungen von auffälligen unterscheiden? [
(Developmental psychological assessment of aging: How can we differentiate normal from abnormal cognitive achievements? ]. Diagnostica, 59, 1–10.2001). Activities of daily living in Alzheimer’s disease: Neuropsychiatric, cognitive and medical illness influences. American Journal of Geriatric Psychiatry, 9, 81–86.
(